Nature cancer · 2024
Dura immunity configures leptomeningeal metastasis immunosuppression for cerebrospinal fluid barrier invasion.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Jiaxu, Zeng Rui, Li Xiaohui, Lu Ying, Wang Zuoyun, Peng Haibao, Chen Hao, Fu Minjie, Zhang Ye, Huang Yang, Chen Wenhan, Wang Xin, Guan Yun, Han Wei, Huang Ruofan, Yao Chengjun, Qin Zhiyong, Chen Lingchao, Chen Liang, Feng Xue, Yang Hanting, Pereira Patrícia M R, Tong Xuemei, Li Bin, Zhang Qiangqiang, Chi Yudan
Аннотация
The cerebrospinal fluid (CSF) border accommodates diverse immune cells that permit peripheral cell immunosurveillance. However, the intricate interactions between CSF immune cells and infiltrating cancer cells remain poorly understood. Here we use fate mapping, longitudinal time-lapse imaging and multiomics technologies to investigate the precise origin, cellular crosstalk and molecular landscape of macrophages that contribute to leptomeningeal metastasis (LM) progression. Mechanically, we find that dura-derived LM-associated macrophages (dLAMs) migrate into the CSF in a matrix metalloproteinase 14 (MMP14)-dependent manner. Furthermore, we identify that dLAMs critically require the presence of secreted phosphoprotein 1 (SPP1) in cancer cells for their recruitment, fostering an immunosuppressed microenvironment characterized by T cell exhaustion and inactivation. Conversely, inhibition of the SPP1-MMP14 axis can impede macrophages from bypassing the border barrier, prevent cancer cell growth and improve survival in LM mouse models. Our findings reveal an unexpectedly private source of innate immunity within the meningeal space, shed light on CSF barrier dysfunction dynamics and supply potential targets of clinical immunotherapy.